{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:11:06Z","timestamp":1791094266175,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.critrevonc.2009.02.001","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T10:13:40Z","timestamp":1237457620000},"page":"156-166","source":"Crossref","is-referenced-by-count":113,"title":["Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy"],"prefix":"10.1016","volume":"73","author":[{"given":"Peyman","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2009.02.001_bib1","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J Clin Oncol"},{"issue":"Suppl.1","key":"10.1016\/j.critrevonc.2009.02.001_bib2","first-page":"S145","article-title":"Distant metastasis: the most common type of early recurrence with adjuvant tamoxifen therapy","volume":"106","author":"Doughty","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"16S","key":"10.1016\/j.critrevonc.2009.02.001_bib3","first-page":"62s","article-title":"Breast cancer relapse and related mortality in US patients with early breast cancer","volume":"23","author":"Lamerato","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib6","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl. 9","key":"10.1016\/j.critrevonc.2009.02.001_bib7","article-title":"Initial adjuvant therapy with anastrozole reduced rates of early breast cancer recurrence and adverse events compared with tamoxifen\u2014data reported on behalf of the ATAC trialists\u2019 group","volume":"17","author":"Houghton","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/annonc\/mdm001","article-title":"Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial","volume":"18","author":"Mauriac","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.mlr.0000166617.68751.5f","article-title":"The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know","volume":"43","author":"Balkrishnan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib10","first-page":"139","article-title":"Oncologist\u2013patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy","volume":"5","author":"Davidson","year":"2007","journal-title":"J Support Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF02850081","article-title":"Medication adherence and persistence: a comprehensive review","volume":"22","author":"Krueger","year":"2005","journal-title":"Adv Ther"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4065\/80.8.983","article-title":"Patients\u2019 understanding of and compliance with medications: the sixth vital sign?","volume":"80","author":"Rosenow","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1677\/ERC-07-0193","article-title":"Menopausal symptoms and adjuvant therapy-associated adverse events","volume":"15","author":"Hadji","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib16","first-page":"42","article-title":"Persistence with drug therapy: a practical approach using administrative claims data","volume":"10","author":"Dezii","year":"2001","journal-title":"Manag Care"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2007-990297","article-title":"The importance of specialist treatment, treatment satisfaction and diabetes education for the compliance of subjects with type 2 diabetes\u2014results from a population-based survey","volume":"116","author":"Arnold-Worner","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","article-title":"A checklist for medication compliance and persistence studies using retrospective databases","volume":"10","author":"Peterson","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2001.19.2.322","article-title":"Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women","volume":"19","author":"Demissie","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib20","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1200\/JCO.2004.11.064","article-title":"Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer","volume":"22","author":"Fink","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib22","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1200\/JCO.2000.18.8.1709","article-title":"What threshold for adjuvant therapy in older breast cancer patients?","volume":"18","author":"Extermann","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000100444","article-title":"Adherence to endocrine therapy for breast cancer","volume":"71","author":"Chlebowski","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","article-title":"Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer","volume":"26","author":"Partridge","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","article-title":"Adherence to tamoxifen over the five-year course","volume":"99","author":"Lash","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(02)00895-1","article-title":"Tamoxifen non-compliance: does it matter?","volume":"3","author":"Murthy","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pec.2004.10.005","article-title":"Adherence beliefs among breast cancer patients taking tamoxifen","volume":"59","author":"Grunfeld","year":"2005","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/01.mlr.0000257193.10760.7f","article-title":"Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use","volume":"45","author":"Kahn","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib32","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.22485","article-title":"Early discontinuation of tamoxifen: a lesson for oncologists","volume":"109","author":"Barron","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1359-6349(06)80201-6","article-title":"Compliance and persistence of tamoxifen and aromatase inhibitors in breast cancer patients","volume":"4","author":"Martin","year":"2006","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib34","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib36","first-page":"S24","article-title":"A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment","volume":"100","author":"Cuzick","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib37","first-page":"S190","article-title":"Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years follow-up","volume":"100","author":"Duffy","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib38","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"issue":"16S","key":"10.1016\/j.critrevonc.2009.02.001_bib40","first-page":"24s","article-title":"Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial","volume":"23","author":"Houghton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib42","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib43","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib44","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/annonc\/mdl177","article-title":"Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer","volume":"17","author":"Moy","year":"2006","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib45","first-page":"S141","article-title":"NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial","volume":"106","author":"Moy","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib46","first-page":"S168","article-title":"Aromatase inhibitors: side effects reported by 622 women","volume":"106","author":"Salgado","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.amjsurg.2006.06.018","article-title":"Side effects of aromatase inhibitors versus tamoxifen: the patients\u2019 perspective","volume":"192","author":"Garreau","year":"2006","journal-title":"Am J Surg"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib48","first-page":"S111","article-title":"Adjuvant aromatase inhibitors in early breast cancer\u2014toxicity and adherence. Important observations in clinical practice","volume":"106","author":"Dent","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib49","series-title":"Presented at ASCO Breast Cancer Symposium; September 7\u20138","article-title":"Discontinuation rates of adjuvant letrozole or anastrozole in breast cancer patients in an electronic medical record database observational study","author":"Crean","year":"2007"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib50","first-page":"S186","article-title":"Adherence with adjuvant anastrozole therapy among women with early stage breast cancer","volume":"100","author":"Partridge","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib51","first-page":"S146","article-title":"Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer","volume":"106","author":"Hadji","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib52","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ejca.2006.03.004","article-title":"Intentional and non-intentional non-adherence to medication amongst breast cancer patients","volume":"42","author":"Atkins","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib53","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1001\/jama.288.22.2880","article-title":"Helping patients follow prescribed treatment: clinical applications","volume":"288","author":"Haynes","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib54","doi-asserted-by":"crossref","first-page":"32s-L37s","DOI":"10.1016\/j.amjmed.2005.12.021","article-title":"Approaches to patient education: emphasizing the long-term value of compliance and persistence","volume":"119","author":"Gold","year":"2006","journal-title":"Am J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib55","first-page":"S261","article-title":"Enhancing communication between oncologists and breast cancer patients","volume":"106","author":"Kirk","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib56","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pec.2004.08.006","article-title":"Preferences for medical collaboration: patient\u2013physician congruence and patient outcomes","volume":"57","author":"Jhang","year":"2005","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib57","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","article-title":"Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II)","volume":"75","author":"Hadji","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib59","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM196903062801004","article-title":"Gaps in doctor\u2013patient communication. Patients\u2019 response to medical advice","volume":"280","author":"Francis","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib60","first-page":"3083","article-title":"Patients need to know","volume":"42","author":"Wengstrom","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib61","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1188\/07.CJON.433-439","article-title":"Aromatase inhibitors and musculoskeletal pain in patients with breast cancer","volume":"11","author":"Winters","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib62","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ejca.2007.03.023","article-title":"Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition?","volume":"43","author":"Jenkins","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jsbmb.2003.07.001","article-title":"The effects of hormone therapy on cognition in breast cancer","volume":"86","author":"Shilling","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib64","doi-asserted-by":"crossref","first-page":"1056s","DOI":"10.1158\/1078-0432.CCR-05-2185","article-title":"Managing patients on endocrine therapy: focus on quality-of-life issues","volume":"12","author":"Whelan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13697130500487224","article-title":"Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life","volume":"9","author":"Gupta","year":"2006","journal-title":"Climacteric"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib66","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2007.12.4180","article-title":"Oncologist communication about emotion during visits with patients with advanced cancer","volume":"25","author":"Pollak","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib67","first-page":"54","article-title":"No one told me I had a choice","author":"Laurent","year":"2007","journal-title":"Cancer World Magazine"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib68","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.breast.2007.02.007","article-title":"Patients\u2019 knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study","volume":"16","author":"Wengstrom","year":"2007","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10549-004-3779-1","article-title":"Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death","volume":"90","author":"Rakovitch","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-2005-869479","article-title":"Pathophysiology and treatment of menopausal hot flashes","volume":"23","author":"Freedman","year":"2005","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2007.10.004","article-title":"Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib72","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/art.21364","article-title":"Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation","volume":"52","author":"Felson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.02.001_bib73","first-page":"S108","article-title":"Comparison of joint problems reported by patients in a randomized adjuvant trial of anastrozole and letrozole","volume":"106","author":"Renshaw","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1359-6349(08)70417-8","article-title":"Guidelines for bone health in postmenopausal women (PMW) with hormone-sensitive breast cancer (HSBC) receiving adjuvant aromatase inhibitor (AI) therapy","volume":"6","author":"Kalder","year":"2008","journal-title":"Eur J Cancer Suppl"},{"issue":"Suppl. 3","key":"10.1016\/j.critrevonc.2009.02.001_bib75","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.breast.2007.10.004","article-title":"Reducing the risk of bone loss associated with breast cancer treatment","volume":"16","author":"Hadji","year":"2007","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib76","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib77","series-title":"Presented at 7th Annual European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, March 28\u201331","article-title":"Good persistence and adherence to bisphosphonates reduces fracture rate in patients with osteoporotic fractures","author":"Gothe","year":"2007"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"issue":"18S","key":"10.1016\/j.critrevonc.2009.02.001_bib79","first-page":"24s","article-title":"Relationship between numeracy and breast cancer patients\u2019 estimates of adjuvant treatment benefit","volume":"24","author":"Lipkus","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.02.001_bib80","unstructured":"AstraZeneca. Patient's Anastrozole Compliance to Therapy Programme (PACT), http:\/\/www.clinicaltrials.gov NCT00555867 [assessed June 19, 2008]."},{"key":"10.1016\/j.critrevonc.2009.02.001_bib81","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1359-6349(08)70581-0","article-title":"Patient's Anastrozole Compliance to Therapy Programme (PACT) influence of the addition of a standardized information and reminder service on compliance in comparison to standard clinical care alone in women with early breast cancer","volume":"6","author":"Hadji","year":"2008","journal-title":"Eur J Cancer Suppl"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842809000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842809000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T19:38:36Z","timestamp":1558208316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842809000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1040842809000286"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2009.02.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}